EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Artificial intelligence-enabled nanomedicine: enhancing drug design and predictive modeling in pharmaceutics

Omnia M Sarhan iD, Mostafa I Gebril, Doaa Elsegaie

Journal of Pharmacy and Pharmacology · 05.03.2026 · 78 (3)

DOI: 10.1093/jpp/rgaf113 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 07.12.2025. Verfasst von Omnia M Sarhan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Badr University in Cairo, Cairo 11829, Egypt. Hauptthemen laut MEDLINE: Artificial Intelligence, Nanomedicine, Drug Design. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 118 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of artificial intelligence (AI) and nanomedicine has initiated a revolutionary phase in pharmaceutical research, facilitating progress in targeted drug delivery, controlled release, and personalized therapeutics. This review explores how AI-driven methods are integrated with nanocarrier systems such as liposomes, polymeric nanoparticles, and dendrimers. By harnessing high-dimensional datasets and predictive modeling, advanced techniques like deep learning, reinforcement learning, and graph neural networks have greatly enhanced pharmacokinetic predictions. As a result, dose–response forecasts have become more accurate, development timelines have shortened, and the experimental workload has been reduced. These technologies confront challenges in data standardization, algorithmic transparency, and regulatory adherence. While agencies such as the Food and Drug Administration and European Medicines Agency continue to update their guidelines, there remains an urgent need for a unified, flexible framework that can keep pace with rapid technological progress. This article calls for stronger cross-disciplinary cooperation among computer scientists, pharmaceutical researchers, and regulatory experts to address these challenges and fully harness AI-Enabled Nanomedicine for transforming personalized drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceNanomedicineDrug DesignHumansDrug Delivery SystemsAnimalsDrug DevelopmentNanoparticles

Stichwörter der Autor:innen

deep learninggraph neural networksnanomedicinepersonalized therapyreinforcement learningtargeted drug delivery

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Badr University in Cairo, Cairo 11829, Egypt.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Misr International University (MIU), Cairo, Egypt.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Heliopolis University, Cairo 11785, Egypt.

ORCID-Profile: Omnia M Sarhan

Zitieren

APA

Sarhan, O. M., Gebril, M. I., & Elsegaie, D. (2026). Artificial intelligence-enabled nanomedicine: enhancing drug design and predictive modeling in pharmaceutics. Journal of Pharmacy and Pharmacology, 78(3). https://doi.org/10.1093/jpp/rgaf113

Vancouver

Sarhan OM, Gebril MI, Elsegaie D. Artificial intelligence-enabled nanomedicine: enhancing drug design and predictive modeling in pharmaceutics. Journal of Pharmacy and Pharmacology. 2026;78(3). doi:10.1093/jpp/rgaf113

BibTeX
@article{Sarhan2026,
  author = {Sarhan, Omnia M and Gebril, Mostafa I and Elsegaie, Doaa},
  title = {Artificial intelligence-enabled nanomedicine: enhancing drug design and predictive modeling in pharmaceutics},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {3},
  doi = {10.1093/jpp/rgaf113}
}
Kostenlos starten →